You have done this properly. Not a fad—a real deficit, tracked, sustained for months, with the training to go with it.
And it worked, in places. Your face is leaner. Your arms are leaner. Your legs are leaner. The waistband has barely moved, and what is there is firm rather than soft—not the kind of fat you can take hold of.
At some point most people conclude they are doing something wrong. Eating more than they think. Not training hard enough. Some hidden failure of discipline that would explain why one part of the body ignored a deficit the rest of it obeyed.
There is a better explanation, and it is anatomical.
At YoungerMeMD it is prescribed as the Tesamorelin program.
You are carrying two different tissues
The fat under your skin—subcutaneous fat—is the fat you can pinch. It is a storage depot, relatively inert, and it does what a calorie deficit tells it to.
Visceral adipose tissue is different. It sits deep in the abdomen, wrapped around your internal organs, and you cannot pinch it. It is metabolically active—it drives inflammation, and it contributes to insulin resistance, cardiovascular risk and metabolic dysfunction.
And the crucial part, directly: it does not respond to caloric restriction the way surface fat does. You can be lean everywhere else and still carry it.
That is the answer to the question at the top of this article. The deficit worked. It worked on the tissue that responds to deficits. The other tissue was never listening.
The firmness is the tell. Subcutaneous fat is soft and mobile. A midsection that is firm and full is often sitting on top of a deeper compartment that a deficit does not reach.
Why it does not respond
Fat is not released by the absence of food alone. It is released by hormonal signals telling the body which stores to mobilize—and visceral adipose tissue is unusually dependent on one of them.
Growth hormone declines from the mid-thirties onward. It is gradual and universal, which is exactly why it is not noticed as an event.
So the situation for most people over forty is a fat depot that requires a hormonal signal to mobilize, and a hormonal signal that has been fading for a decade or more. Cutting calories harder does not restore the signal—it just makes the body take the energy from somewhere it can, which is usually subcutaneous fat and muscle.
Which is how you end up leaner in the face and arms, no different at the waist, and with less muscle than you started with.
Why this is worth taking seriously beyond appearance
It is tempting to treat this as a vanity problem that has proved stubborn. It is not.
Visceral fat is directly linked to cardiovascular disease, type 2 diabetes and systemic inflammation. It drives inflammation and contributes to insulin resistance and metabolic dysfunction while it sits there.
Reducing it is not cosmetic—it is one of the most impactful things you can do for long-term health and longevity. That is the reason to address it, and it is a better reason than the waistband.
What Tesamorelin does about it
Tesamorelin is a GHRH analog—it mimics growth hormone-releasing hormone, prompting your pituitary to restore the natural growth hormone pulses your body has been producing less of since your mid-thirties.
As growth hormone levels normalize, the body preferentially breaks down visceral fat while preserving lean muscle.
That is the specific reversal of the problem described above. Not a bigger deficit—a restored signal, to the tissue that was waiting on one.
It is the only FDA-approved peptide specifically proven to reduce visceral fat, used off-label at YoungerMeMD for adult metabolic and longevity optimization. Clinical studies show reductions of 15–18% in visceral adipose tissue over several months of consistent use, and as visceral fat decreases, triglycerides, inflammatory markers and insulin sensitivity improve with it.
There is also a lean-mass difference worth naming. Unlike caloric restriction, which often takes lean mass with it, Tesamorelin tends to preserve—and in some cases improve—lean muscle tissue as visceral fat decreases.
What it is not
It is not an appetite suppressant. It does not work on appetite or gastric emptying and has nothing in common with a GLP-1 medication. If your genuine constraint is how much you eat, this is not the therapy for that.
It is not a license to stop. The patient we see for it has already done the diet, the training and the lifestyle. Your clinical response is better with consistent sleep, stress management, regular physical activity and balanced nutrition—all of which directly influence growth hormone dynamics and metabolic function.
It is not fast. Early improvements in energy and sleep within the first few weeks; body composition and visceral fat changes at six to twelve weeks; the most significant results at three to six months.
And it may not move the scale much. Visceral fat is a small proportion of total body mass, so the change in metabolic markers and body composition can be substantial while the weight change is modest. Judge this by composition and labs, not by the number.
What else could be going on
Stubborn abdominal fat has more than one cause, and growth hormone is one of several.
Insulin resistance and metabolic dysfunction can drive the same pattern, and there the more direct answer may be MOTS-c—described as our top recommendation for menopause weight gain because it addresses the mitochondrial dysfunction and insulin resistance driving stubborn visceral fat during menopause.
Hormonal change more broadly matters. In women, estrogen decline impairs mitochondrial function and changes fat distribution. In men, declining testosterone does something similar. Cortisol from genuine chronic stress preferentially deposits fat in exactly this compartment. Thyroid dysfunction affects the whole picture.
And sometimes the diet was not what it seemed, which is worth ruling out honestly before reaching for a prescription.
This is why our provider team evaluates labs, history and goals before any protocol is built, and why nothing is prescribed without the complete picture.
Safety
Tesamorelin is generally very well tolerated. Some patients notice mild injection site irritation, fluid retention, or brief adjustment symptoms during the first few weeks as growth hormone levels normalize; these are typically mild and self-limited.
It should be used with caution in patients with active malignancy or a history of certain cancers, and it should not be used during pregnancy or breastfeeding. Tell us about all current medications, supplements and existing health conditions.
It is given as a small, fine-needle subcutaneous injection at home in the evening, five nights out of seven, with two rest nights built in — a schedule that mirrors natural growth hormone pulsatility and prevents receptor desensitization. Full training is provided.
If your midsection ignored a deficit that the rest of you obeyed, that is information. It points at a particular tissue with a particular requirement.
Full details on the Tesamorelin page, or book a consultation.
This article is for general education and is not medical advice. Changes in body composition have multiple causes requiring proper evaluation. Tesamorelin is FDA-approved for visceral fat reduction and used off-label at YoungerMeMD under physician supervision. It should be used with caution in patients with active malignancy or a history of certain cancers, and not during pregnancy or breastfeeding.
